Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2024-06-21 Earnings Release
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
Earnings Release Classification · 95% confidence The document is explicitly titled "Press Release" and announces new data presentations for Sanofi's hemophilia treatments (ALTUVIIIO and fitusiran) at the ISTH Congress. It also mentions the acceptance of a New Drug Application (NDA) for fitusiran by the FDA. This content is a high-level summary of recent corporate and clinical developments intended for immediate public release, which aligns perfectly with the definition of an Earnings Release (ER) or a general announcement. Since it focuses on clinical trial updates and regulatory milestones rather than comprehensive financial results (like a 10-K or IR), and it is a direct announcement rather than a notice about a report being published (RPA), the most appropriate classification is Earnings Release (ER), as these press releases often accompany or precede quarterly financial reporting periods, even if the focus here is clinical data. Given the context of presenting interim phase 3 data and regulatory updates, ER is the best fit among the options provided for a major corporate announcement of this nature. FY 2024
2024-06-21 English
Communiqué de presse : ISTH : De nouvelles données sur ALTUVIIIO et le fitusiran confortent le leadership de Sanofi dans le traitement de l’hémophilie
Earnings Release Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and details new data being presented at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) regarding Sanofi's hemophilia treatments (ALTUVIIIO and fitusiran). It summarizes clinical trial results (XTEND-ed, ATLAS) and mentions regulatory milestones (FDA review for fitusiran). This format—a formal announcement summarizing scientific/clinical updates intended for the public and investors, often released ahead of or concurrent with a conference presentation—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is announcing scientific/clinical progress rather than just a dividend or management change, it fits best as an Earnings Release (ER) which often includes key operational/pipeline updates, or potentially a Regulatory Filing (RNS) if it were less structured. Given the structure and focus on presenting new data/results, ER is the most appropriate fit among the specific options, as these press releases often accompany quarterly financial reporting periods, even if the primary focus here is scientific data presentation. It is not a Report Publication Announcement (RPA) because it contains substantial content, not just a notice that a report is available. FY 2024
2024-06-21 French
Communiqué de presse : Sanofi et Biovac pionniers de la production de vaccins contre la polio en Afrique
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a strategic partnership between Sanofi and Biovac regarding local vaccine production in Africa. It contains quotes from executives, background information on polio eradication, and contact details for media and investors. This format is characteristic of an official announcement intended for immediate public dissemination, rather than a comprehensive regulatory filing (like 10-K or IR) or a formal report itself. Since it is a press release announcing a significant business development (partnership/collaboration), it does not fit perfectly into the specific categories like ER (Earnings Release) or CAP (Capital/Financing Update). Given the nature of the announcement—a significant corporate action/news release—and the lack of a more specific fit among the provided options, the most appropriate general category for a non-standard, important corporate announcement that isn't a financial report or management change is the fallback category, Regulatory Filings (RNS), which often encompasses press releases that don't fit elsewhere, or potentially a general announcement category if one existed. However, looking closely at the definitions, this is a general corporate news announcement. Since RNS is defined as "General regulatory announcements and fallback category for miscellaneous filings," and this is a press release announcing a strategic move, RNS is the best fit among the choices provided, as it is not an ER, CT, or a specific report type.
2024-06-20 French
Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'Press Release' and announces a strategic partnership between Sanofi and Biovac regarding polio vaccine manufacturing in Africa. It contains quotes from executives, background information on polio eradication, and standard sections like 'About Sanofi' and 'Media Relations/Investor Relations'. This format is characteristic of an initial announcement of significant corporate news, which aligns best with the 'Earnings Release (ER)' category if it were financial results, but since it is a major operational/strategic announcement, it is most closely related to a general corporate announcement. However, none of the definitions perfectly capture a strategic partnership press release. Given the options, this is not a formal regulatory filing (10-K, AR, IR), nor is it a presentation (IP, AGM-R), nor a transcript (CT). It is a public announcement. Since it is not a specific financial report or a notice of a report publication (RPA), and it is a significant corporate event announcement, the closest fit among the provided options that covers general corporate news not covered elsewhere is often the 'Regulatory Filings (RNS)' category, which serves as a broad category for miscellaneous regulatory/corporate announcements not fitting specific codes. However, if we strictly interpret the definitions, this is a high-level corporate announcement. Since it is not a financial report, and not a specific governance/insider/capital event, RNS is the best fallback. It is not an Earnings Release (ER) as it does not contain financial results.
2024-06-20 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers'. It provides a table detailing the number of shares and voting rights as of May 31, 2024, referencing French commercial code and AMF regulations. This specific disclosure relates to the total number of voting rights and shares, which is a mandatory periodic regulatory filing in France, often related to capital structure updates or general meeting prerequisites. While it is a specific regulatory disclosure, it doesn't perfectly match the definitions for DVA (Voting Results), SHA (Share Issue), or POS (Transaction in Own Shares). It is a specific regulatory update concerning share capital and voting rights. Given the options, this type of mandatory disclosure regarding the total number of voting rights and shares is most closely aligned with a general regulatory filing or a specific capital/share structure update. Since it is a formal, periodic disclosure mandated by financial regulators (AMF), and it deals with the composition of capital and voting rights, it fits best under the general 'Regulatory Filings' (RNS) as a fallback, or potentially 'Share Issue/Capital Change' (SHA) if the intent is to report the current state of capital. However, since it is a routine disclosure of voting rights count, and not an announcement of a change (like a new issue or buyback), RNS is the most appropriate general regulatory category for this specific type of mandatory information release that doesn't fit a more specific operational category like ER or IR. The document length is short (1513 chars) and it is a direct disclosure, not an announcement of another report.
2024-06-12 French
Sanofi: Information concerning the total number of voting rights and shares – May 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns the 'total number of voting rights and shares' pursuant to French Commercial Code and AMF regulations. It provides a table detailing the total number of issued shares and the corresponding voting rights as of a specific date (May 31, 2024). This type of mandatory disclosure regarding share capital structure and voting power is a specific regulatory filing. Among the provided definitions, none perfectly match a routine 'Total Voting Rights' disclosure, which is often required monthly or quarterly in European jurisdictions. However, it is a specific regulatory announcement concerning share capital structure, which is closely related to share issues or capital changes (SHA) or general regulatory filings (RNS). Given the highly specific nature of the disclosure (voting rights calculation based on specific articles), and the lack of a dedicated code for 'Total Voting Rights', it is best classified as a general Regulatory Filing (RNS) or potentially related to Share Issue/Capital Change (SHA). Since it is a direct regulatory disclosure about the current state of voting rights, RNS (Regulatory Filings - general fallback for specific regulatory disclosures) is the most appropriate fit, as SHA usually implies an action (issue/buyback) rather than a periodic status report. The document is short and is a direct disclosure, not an announcement of another report.
2024-06-12 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.